FibroBiologics, Inc. develops fibroblast-based and fibroblast-derived therapies for chronic diseases and regenerative medicine applications. News about FBLG centers on its clinical-stage cell-therapy platform, including CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and related programs in wound healing, disc degeneration, orthopedics, cancer, immune aging, and pulmonary inflammatory conditions.
Company updates commonly cover clinical-trial preparation and drug-product manufacturing, preclinical data from fibroblast spheroids and thymic organoid research, scientific meeting presentations, shareholder communications, quarterly financial results, Nasdaq listing compliance, and capital-planning actions that support development of its fibroblast technology pipeline.
FibroBiologics (Nasdaq: FBLG) reported preclinical animal data showing cartilage repair within four weeks after a single injection of fibroblast-spheroid-derived chondrocyte spheroids (FSdCS) in induced joint defects. According to FibroBiologics, these in vivo results provide proof of concept for a regenerative approach that aims to repair damaged joints rather than only manage symptoms.
The company highlights a four-day manufacturing process to convert spheroids into chondrocyte spheroids, positioning FSdCS as a potential lower-cost and scalable cell-therapy option compared with conventional timelines. FibroBiologics describes FSdCS as three-dimensional clusters of proliferating cartilage-producing cells designed for direct injection into damaged joints. The data are characterized as preliminary preclinical findings that will guide design of future studies.
FibroBiologics (Nasdaq: FBLG) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,691,147, titled “Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment.” The patent covers methods using fibroblasts to enhance engraftment, survival, and long-term function of transplanted pancreatic islets in Type 1 diabetes.
The technology describes fibroblast-based compositions that improve the microenvironment for transplanted islets, potentially increasing islet viability and donor tissue utilization. FibroBiologics, a clinical-stage biotech focused on fibroblast-based therapies, now holds 270+ issued and pending patents across multiple chronic disease areas.
FibroBiologics (Nasdaq: FBLG) announced that the European Patent Office has granted European Patent No. EP 3043825 B1, entitled “Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells.” The patent contains 12 claims covering Sox9-based gene therapy compositions using expression vectors to convert fibroblasts into cartilage-producing cells for individuals needing cartilage repair.
The patent can be validated in selected European Patent Convention states, extending protection for this fibroblast-centered cartilage regeneration approach into major European markets and supporting the company’s orthopedics and degenerative disc indications.
FibroBiologics (Nasdaq: FBLG) reported second quarter 2026 results and advanced its fibroblast-based pipeline, highlighted by first patient dosing in the Phase 1/2 trial of wound-care candidate CYWC628 for diabetic foot ulcers. The company completed three cGMP batches of CYWC628 and plans interim trial results in 2H 2026, with primary safety and efficacy data expected by year-end 2026.
FibroBiologics strengthened its balance sheet with a $9.0 million private placement ($3.0 million upfront and up to approximately $6.0 million via warrant exercises) and a $3.0 million public offering. For Q2 2026, research and development expenses were about $1.7 million versus $2.0 million a year earlier, while general and administrative expenses were stable at $2.4 million. Net loss was approximately $4.1 million, and cash and cash equivalents totaled about $3.5 million at June 30, 2026.
The company reported preclinical burn-wound data using human dermal fibroblast spheroids, received a USPTO notice of allowance for a wound-healing patent, and filed a provisional patent on oral delivery systems for fibroblast-based therapeutics. Upcoming milestones include an anticipated IND clearance for psoriasis candidate CYPS317 and planned IND submission for multiple sclerosis candidate CYMS101 in Q4 2026, as well as an IND amendment for its degenerative disc disease program.
FibroBiologics (Nasdaq:FBLG), a clinical-stage biotech focused on fibroblast-based therapies for chronic diseases, appointed microbiologist and retired NASA astronaut Kathleen “Kate” Rubins, Ph.D. to its Board of Directors.
Rubins has served on the company’s Scientific Advisory Board since 2022 and brings experience in genomics, immune response to infection, and space biomedicine, including sequencing DNA on the ISS and leading infectious disease research at MIT’s Whitehead Institute.
FibroBiologics (Nasdaq:FBLG) completed manufacturing the third batch of its CYWC628 drug product for an ongoing Phase 1/2 clinical trial in diabetic foot ulcer patients. The batch was produced under cGMP and is undergoing safety and quality testing before clinical release.
Upon release, FibroBiologics expects to have enough CYWC628 to complete the trial, with surplus doses for future R&D and reduced short-term cash outlays by avoiding additional vial manufacturing. The company anticipates reporting statistically significant interim data in Q3 2026.
FibroBiologics (Nasdaq:FBLG) announced that its Founder and CEO Pete O'Heeron and CSO Hamid Khoja, Ph.D., will join a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference, held June 30–July 1, 2026.
The session is scheduled for 1:00 p.m. ET on June 30, 2026 and will be moderated by Matthew Caufield, Senior Research Healthcare Analyst at H.C. Wainwright & Co. FibroBiologics will also be available for one-on-one investor meetings during the event.
FibroBiologics (NASDAQ:FBLG) closed a private placement raising approximately $3.0 million in gross proceeds through 4,081,633 common shares (or pre-funded warrants) plus accompanying series A and short-term series B warrants priced at $0.735 per share.
Total potential gross proceeds from full cash exercise of all warrants are about $6.0 million, with funds intended for working capital and general corporate purposes.
FibroBiologics (NASDAQ:FBLG) entered agreements for a private placement of 4,081,633 shares (or pre-funded warrants) plus series A and short-term series B warrants, all priced at-the-market at $0.735 per share under Nasdaq rules.
The deal is expected to raise about $3.0 million upfront, with up to approximately $6.0 million in additional gross proceeds if all warrants are exercised. Closing is expected on or about June 29, 2026, with net proceeds earmarked for working capital and general corporate purposes.
FibroBiologics (Nasdaq:FBLG) received a USPTO Notice of Allowance for U.S. Patent Application No. 18/184,726 covering topical fibroblast spheroid therapy for wound healing. The 19 allowed claims address methods to treat and accelerate healing of wounds using 3D spheroid fibroblasts with or without fibroblast-derived materials.
The patent supports the ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers, a common chronic wound. Allowed claims specifically include topical treatment of chronic wounds and individuals with diabetes, closely matching FibroBiologics’ lead wound-healing program.